GlaxoSmithKline is paying $176m for a 10% stake in the RNA drug developer in connection with a strategic partnership agreement.
Germany-based RNA therapy developer CureVac signed a strategic partnership agreement with pharmaceutical firm GlaxoSmithKline (GSK) today that will include a €150m ($176m) equity investment.
GSK will also make a $141m upfront cash payment to CureVac and a reimbursable one-time payment of $35m to secure manufacturing capacity upon certification of a facility the company currently has under construction. The deak will give GSK a 10% stake in CureVac.
Spun out of Eberhard Karls University of Tübingen in 2000, CureVac is developing…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
